May 15, 2019 09:56 AM EDT
R&D
Pharma

Im­muno­Gen shares tank (again) af­ter the FDA nix­es a shot at an OK for its armed an­ti­body in wake of a failed PhI­II

John Carroll

Editor & Founder

Im­muno­Gen $IMGN just com­pound­ed its woes with their lead drug.

Two months af­ter ac­knowl­edg­ing that their an­ti­body-drug con­ju­gate mirve­tux­imab so­rav­tan­sine failed a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times